New Delhi, Aug. 12 -- Marksans Pharma shares crashed 14.28% in today's session (August 12) to hit a four-month low of Rs.180 apiece after the company reported weak June quarter numbers. Net profit fell 34.7% YoY to Rs.58.2 crore, weighed down by weak performance in key regions, including the UK & Europe and Australia & New Zealand.

Profitability was also impacted by higher employee costs due to new hires at the acquired facility, as well as a one-time Expected Credit Loss (ECL) provision of Rs.10.48 crore for the Emerging Market Division.

The revenue from the UK & Europe market dropped 19% YoY and 25.7% QoQ to Rs.203.8 crore, while revenue from Australia & New Zealand declined 13.1% YoY and 25% QoQ to Rs.57 crore.

The company said, "We...